- Management will hold one-on-one meetings with institutional investors and analysts
- The company recently signed an exclusive option agreement with the Applied Biomedical Science Institute (ABSI) to license technology for HER2 and HER3
BRIDGEWATER, NJ, February 28, 2023 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. HELP (“Hillstream” or the “Company”), a biotechnology company developing therapeutic candidates that target drug-resistant and devastating cancers using ferroptosis, an emerging novel anticancer mechanism that leads to iron-mediated cell death, and novel biologics targeting immuno-oncology attend the 35th Annual Meeting ROTH conferencetaking place March 12-14 at The Ritz-Carlton Hotel in Dana Point, California.
“We look forward to attending Roth this year and hosting one-on-one meetings with members of the investment community. The small-cap ecosystem that Roth has created is an incredible opportunity to share our investment thesis and showcase our therapeutic candidates targeting drug-resistant and devastating cancer,” said Randy Milby, CEO of Hillstream.
The company recently held its Virtual R&D Day on February 14thth2023 to discuss its preclinical study of its lead drug candidate HSB-1216 along with other updates on its pipeline candidates and tumor targeting platform Quatramer™.
To arrange a meeting with the management team on the 35thth Annual ROTH Conference, please email investorrelations@hillstreambio.com or visit https://www.meetmax.com/sched/event_89809/conference_home.html.
About the 35th Roth Annual Meeting
The 35th Annual ROTH Conference, hosted by Roth MKM, will take place March 12-14, 2023 and will feature executives from approximately 500 private and public companies from a variety of industries including AgTech, consumer, energy, health and wellness, Healthcare, Industrial Growth, Metals & Mining, Sustainability, Services & Technology. The conference format includes 1-on-1 and small group meetings, analyst-picked fireside chats,…
[ad_2]
Source story
